The trajectory of Sildenafil presents a complex picture for those considering investment. While the initial launch generated substantial gains, the lapse of its exclusive rights opened the floodgates to off-brand competitors, dramatically diminishing sales. This poses a particular dilemma for pharmaceutical companies relying on related blockbuster

The story of Viagra, and its developer copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in income, its patent expiration created a flood of knock-off medications, significantly eroding its position . While some firms may seek to capitalize on similar conditions , the existing landscape demands